FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 260 filers reported holding FATE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,090 | -89.2% | 984 | -75.7% | 0.00% | – |
| Q2 2023 | $19,297 | +5.8% | 4,054 | +26.7% | 0.00% | – |
| Q1 2023 | $18,234 | -20.8% | 3,199 | +40.2% | 0.00% | -100.0% |
| Q4 2022 | $23,015 | -11.5% | 2,281 | +98.2% | 0.00% | 0.0% |
| Q3 2022 | $26,000 | -3.7% | 1,151 | +7.6% | 0.00% | 0.0% |
| Q2 2022 | $27,000 | -20.6% | 1,070 | +22.8% | 0.00% | 0.0% |
| Q1 2022 | $34,000 | 0.0% | 871 | +48.1% | 0.00% | 0.0% |
| Q4 2021 | $34,000 | -35.8% | 588 | -34.7% | 0.00% | -50.0% |
| Q3 2021 | $53,000 | -32.9% | 901 | -0.7% | 0.00% | -33.3% |
| Q2 2021 | $79,000 | +393.8% | 907 | +372.4% | 0.00% | +200.0% |
| Q1 2021 | $16,000 | -5.9% | 192 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $17,000 | +112.5% | 192 | -5.4% | 0.00% | – |
| Q3 2020 | $8,000 | +60.0% | 203 | +31.0% | 0.00% | – |
| Q2 2020 | $5,000 | +66.7% | 155 | 0.0% | 0.00% | – |
| Q1 2020 | $3,000 | – | 155 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
| Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
| Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
| Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
| Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
| Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
| DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
| Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
| Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |